What is Thymosin Alpha-1 and how does it activate innate immunity through TLR signaling?

Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid immunomodulatory peptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH with N-terminal acetylation) originally isolated from thymosin fraction 5 of calf thymus. Unlike thymulin which primarily affects T-cell differentiation in the thymus, Tα1 functions as a potent activator of innate and adaptive immunity through Toll-like receptor (TLR) signaling pathways. Mechanistically: (1) TLR activation - Tα1 acts as an endogenous TLR agonist, particularly engaging TLR2 and TLR9 on dendritic cells (DCs), macrophages, and other antigen-presenting cells (APCs). TLR engagement triggers MyD88-dependent signaling cascades activating NF-κB and IRF transcription factors. (2) Dendritic cell maturation - Tα1 promotes DC maturation characterized by upregulation of MHC class II, CD80, CD86 costimulatory molecules, and production of IL-12, a key cytokine driving Th1 differentiation. Mature DCs enhance T-cell priming and antigen presentation. (3) Th1 cytokine production - Through DC activation and direct T-cell effects, Tα1 skews immune responses toward Th1 phenotype with increased IFN-γ, IL-2, and TNF-α production while reducing Th2 cytokines (IL-4, IL-10). This Th1 bias enhances cell-mediated immunity critical for intracellular pathogen clearance and anti-tumor responses. (4) NK cell and CTL activation - Tα1 enhances natural killer (NK) cell cytotoxicity and cytotoxic T-lymphocyte (CTL) function through increased perforin/granzyme expression and IFN-γ production, strengthening innate and adaptive cytotoxic responses. (5) Regulatory effects - While promoting Th1 immunity, Tα1 also modulates excessive inflammation by inducing regulatory T-cells (Tregs) and anti-inflammatory cytokines preventing autoimmune pathology. (6) Antiviral and antimicrobial immunity - TLR-mediated interferon (IFN-α/β) production creates antiviral state, while enhanced phagocyte function and antimicrobial peptide expression improve bacterial clearance. Research applications include innate immunity studies, TLR signaling research, vaccine adjuvant development, infectious disease models (viral hepatitis, HIV, influenza, sepsis), cancer immunotherapy investigating DC vaccines and checkpoint inhibitor combinations, and autoimmune disease research examining Th1/Th2 balance modulation.

How does Thymosin Alpha-1 differ from Thymosin Beta-4 in mechanism and applications?

Despite similar naming, Thymosin Alpha-1 (Tα1) and Thymosin Beta-4 (TB-500, Tβ4) are structurally and functionally distinct peptides with non-overlapping research applications: (1) Structure - Tα1 is a 28-amino-acid peptide (MW ~3108 Da) with N-terminal acetylation derived from prothymosin alpha proteolytic processing, while TB-500 is a 43-amino-acid peptide (MW ~4963 Da) with different sequence. They share thymic origin but are encoded by different genes. (2) Primary mechanisms - Tα1 functions as immunomodulator activating TLR signaling, dendritic cells, and Th1 immunity (IFN-γ, IL-12, IL-2) making it potent activator of cell-mediated immune responses against infections and cancer. TB-500 is actin-sequestering peptide regulating cytoskeletal dynamics, promoting cell migration, angiogenesis, wound healing, and tissue repair with anti-inflammatory properties - primarily involved in regenerative processes rather than direct immune activation. (3) Receptor targets - Tα1 engages TLR2/TLR9 on immune cells and potentially other pattern recognition receptors driving inflammatory and antimicrobial programs. TB-500 binds G-actin preventing polymerization, modulates cytoskeletal remodeling, and may interact with other intracellular targets regulating cell motility and gene expression. (4) Cytokine profiles - Tα1 strongly promotes pro-inflammatory Th1 cytokines (IFN-γ, IL-12, TNF-α) enhancing cellular immunity. TB-500 tends toward anti-inflammatory effects reducing pro-inflammatory cytokines while promoting tissue repair factors (VEGF, HGF). (5) Research applications - Choose Tα1 for infectious disease research (viral, bacterial, fungal), vaccine development as adjuvant, cancer immunotherapy enhancing anti-tumor immunity, TLR signaling studies, DC biology, Th1/Th2 balance investigations, and immunodeficiency models requiring immune stimulation. Choose TB-500 for wound healing research, cardiovascular repair (post-MI), muscle/tendon injury models, angiogenesis studies, neurological injury, hair follicle biology, and anti-fibrotic research. (6) Combination potential - Some research combines Tα1 + TB-500 investigating synergistic tissue repair (TB-500) with reduced infection risk (Tα1 immune enhancement), particularly in wound healing or post-surgical recovery models.

What research applications benefit from Thymosin Alpha-1's TLR activation and Th1 promotion?

Thymosin Alpha-1 excels in research requiring innate immune activation and Th1-biased adaptive immunity: (1) Infectious disease models - Tα1 enhances clearance of intracellular pathogens (viruses, mycobacteria, intracellular bacteria) requiring cell-mediated immunity. Studies in viral hepatitis B/C models show Tα1 increases HBsAg/HCV viral clearance, improves ALT normalization, and enhances IFN-α responsiveness. HIV research investigates Tα1 as immune reconstitution adjunct restoring CD4+ counts and antiviral immune responses. Influenza, respiratory syncytial virus (RSV), and emerging viral pathogen studies use Tα1 to boost antiviral immunity. Sepsis models examine whether Tα1 prevents immunoparalysis (the immune suppression following severe infection) by maintaining monocyte HLA-DR expression and cytokine production. (2) Vaccine adjuvant research - Tα1's DC-activating and Th1-promoting properties make it candidate vaccine adjuvant. Studies combine Tα1 with hepatitis B, influenza, cancer vaccines, or COVID-19 vaccines measuring enhanced antibody titers, increased T-cell responses, and improved seroconversion rates. The TLR agonist activity mimics pathogen-associated molecular patterns (PAMPs) providing 'danger signals' enhancing vaccine immunogenicity. (3) Cancer immunotherapy - Tα1 promotes anti-tumor immunity through multiple mechanisms: DC maturation improves tumor antigen presentation, Th1 cytokine production enhances CTL activity, NK cell activation increases tumor cell lysis, and immune checkpoint modulation (Tα1 can upregulate PD-L1 on tumor cells making them targets for anti-PD-1/PD-L1 therapy). Research combines Tα1 with checkpoint inhibitors (anti-PD-1, anti-CTLA-4), DC vaccines, CAR-T therapy, or chemotherapy investigating synergistic anti-tumor effects. Clinical trial data in melanoma, hepatocellular carcinoma, non-small cell lung cancer show improved outcomes with Tα1 combinations. (4) Immunodeficiency research - Primary immunodeficiencies, AIDS, chemotherapy-induced immunosuppression, post-transplant immunocompromise - Tα1 can restore immune function by activating remaining immune cells, enhancing lymphocyte proliferation, and normalizing cytokine production. (5) Autoimmune disease modulation - While Tα1 promotes Th1 immunity, it also induces Tregs preventing excessive inflammation. Research in autoimmune hepatitis, rheumatoid arthritis, multiple sclerosis models examines Tα1's ability to restore immune balance. (6) TLR signaling research - Using Tα1 as tool compound to study TLR2/TLR9 pathways, MyD88 signaling, NF-κB activation kinetics, and interferon regulatory factor (IRF) activation.

What purity and quality standards does your Thymosin Alpha-1 meet for research?

Our Thymosin Alpha-1 exceeds >98% purity verified by reverse-phase HPLC demonstrating retention time characteristic of the 28-amino-acid sequence with N-terminal acetylation. Each batch undergoes comprehensive quality control: mass spectrometry confirmation of molecular weight (~3108 Da) validating the complete Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn sequence, peptide sequencing via MS/MS fragmentation or Edman degradation verifying each residue and critically confirming N-terminal acetylation (acetyl group = +42 Da; non-acetylated Tα1 shows altered bioactivity and faster degradation), amino acid composition analysis quantifying each residue confirming sequence fidelity, functional bioassays measuring immunological activity including dendritic cell maturation assays treating immature DCs (monocyte-derived or bone marrow-derived) with dose-escalating Tα1 and measuring CD80/CD86/MHC-II upregulation via flow cytometry plus IL-12 secretion via ELISA demonstrating DC activation with EC50 quantification, Th1 cytokine production assays using peripheral blood mononuclear cells (PBMCs) or splenocytes treated with Tα1 measuring IFN-γ, IL-2, TNF-α production via multiplex cytokine assays or ELISA validating Th1-polarizing activity, TLR reporter assays using HEK293 cells stably expressing TLR2 or TLR9 with NF-κB-luciferase reporters measuring Tα1-induced luciferase activity confirming TLR agonist function, NK cell cytotoxicity assays demonstrating Tα1 enhances NK-mediated target cell lysis measured by chromium release or calcein-AM release assays, T-cell proliferation assays showing Tα1 enhances mitogen-stimulated T-cell expansion, endotoxin testing (<0.1 EU/mg via LAL assay), and comprehensive Certificate of Analysis. The N-terminal acetylation is critical for bioactivity and protease resistance - quality control confirms acetylation via mass spec (mass difference) and Edman sequencing (acetylated N-terminus blocks first cycle). For maximal research reproducibility, we recommend reconstitution in sterile water or PBS avoiding acetate buffers which can interfere with N-terminal acetyl group analysis if researchers perform independent verification.

How should Thymosin Alpha-1 be stored and reconstituted for immunological research?

Thymosin Alpha-1 storage and handling protocols: (1) Lyophilized storage - Store at -20°C in original sealed vials for 24+ months stability. The lyophilized 28-amino-acid peptide with N-terminal acetylation remains stable when dry and frozen. Avoid repeated temperature fluctuations; maintain consistent -20°C storage. (2) Reconstitution - Add sterile water, bacteriostatic water (0.9% benzyl alcohol), or phosphate-buffered saline (PBS, pH 7.2-7.4) slowly down vial wall, gently swirl (never shake) until dissolved at typical concentration 0.1-5 mg/mL. Allow 2-3 minutes for complete dissolution. For immunological assays, PBS reconstitution is often preferred as it maintains physiological pH and osmolarity. (3) Reconstituted solution storage - Refrigerate at 2-8°C and use within 14-21 days. The 28-AA peptide with N-terminal acetyl protection shows good stability under refrigeration, but prolonged storage can cause aggregation or oxidation of methionine residues. For experiments extending beyond 2-3 weeks, aliquot reconstituted solution into single-use sterile vials, store at -20°C, and thaw fresh aliquot for each experiment avoiding freeze-thaw cycles. (4) pH considerations - Maintain pH 6.5-7.5 for optimal stability. Extreme acidic pH can promote deamidation of Asn/Gln residues and Asp isomerization, while extreme basic pH causes peptide bond hydrolysis. (5) Preventing oxidation - Tα1 contains no cysteine residues (no disulfide bonds), but does contain one methionine (Met-11). Prolonged exposure to atmospheric oxygen can oxidize methionine to methionine sulfoxide reducing bioactivity. For long-term storage or oxidation-sensitive experiments, consider reconstituting under nitrogen/argon atmosphere or adding antioxidants (0.1% ascorbic acid, though this must be validated for specific assays to ensure no interference). (6) Concentration optimization - For cell-based bioassays (DC maturation, cytokine production, NK cytotoxicity), typical working concentrations range 0.1-10 μg/mL (approximately 30 nM to 3 μM). Prepare stock solution at 1-5 mg/mL and dilute in assay medium to working concentrations. (7) Sterility - Use aseptic technique for reconstitution, especially for in vivo research or primary cell assays. Bacteriostatic water provides antimicrobial protection for multi-dose vials.

What is the significance of N-terminal acetylation in Thymosin Alpha-1 bioactivity?

The N-terminal acetylation of Thymosin Alpha-1 (acetyl-Ser-1) is critical for biological activity, stability, and protease resistance: (1) Aminopeptidase protection - Peptides with free N-terminal amino groups are rapidly degraded by aminopeptidases (exopeptidases sequentially cleaving N-terminal amino acids). N-terminal acetylation blocks aminopeptidase access, dramatically extending Tα1 plasma half-life. Non-acetylated Tα1 shows 5-20 fold faster degradation in serum. (2) Conformational effects - The acetyl group (CH₃CO-) at the N-terminus influences peptide backbone conformation. NMR and circular dichroism studies show acetylated Tα1 adopts specific secondary structure elements (beta-turns, potential helical regions) important for receptor binding and immune cell activation. Non-acetylated forms may have altered conformations reducing TLR binding affinity. (3) Bioactivity correlation - Comparative studies demonstrate acetylated Tα1 shows superior DC maturation, cytokine induction, and TLR activation compared to non-acetylated variants. DC activation assays typically show 3-10 fold higher potency (lower EC50) for acetylated vs non-acetylated Tα1. (4) Biosynthesis - In vivo, Tα1 is generated by proteolytic cleavage of prothymosin alpha, and the serine at position 1 of Tα1 (position 2 of prothymosin alpha) is post-translationally acetylated by N-acetyltransferases. This natural modification is essential for physiological Tα1 function. (5) Synthetic production - Chemical synthesis via solid-phase peptide synthesis (SPPS) must incorporate N-terminal acetylation either during synthesis (using acetylated amino acid building block or acetylating the completed peptide on resin before cleavage) or post-synthetically. Quality control must confirm acetylation presence and distinguish it from non-acetylated contaminants. (6) Analytical verification - Mass spectrometry distinguishes acetylated (MW ~3108 Da) from non-acetylated Tα1 (MW ~3066 Da, -42 Da difference from loss of acetyl group). Edman sequencing shows blocked N-terminus (no amino acid released in first cycle) for acetylated peptides vs identifiable serine for non-acetylated form. (7) Research implications - When comparing Tα1 batches or literature data, researchers must verify acetylation status as non-acetylated preparations may produce inconsistent or reduced immunological effects leading to non-reproducible results. Our quality control explicitly confirms N-terminal acetylation in every batch ensuring reproducible TLR activation and immune modulation.

Can Thymosin Alpha-1 be combined with other immunomodulators or cancer therapies?

Yes! Thymosin Alpha-1 combinations enable synergistic immune modulation and therapeutic research: (1) Tα1 + Immune Checkpoint Inhibitors - Combining Tα1 (promoting DC maturation, Th1 immunity, CTL activation) with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies in cancer models demonstrates synergistic anti-tumor effects. Tα1 increases tumor-infiltrating lymphocytes (TILs) and reverses T-cell exhaustion while checkpoint blockade removes inhibitory signals, resulting in enhanced tumor clearance. Clinical trials in melanoma, hepatocellular carcinoma, lung cancer show improved response rates and progression-free survival with Tα1 + checkpoint inhibitor combinations vs monotherapy. (2) Tα1 + Chemotherapy or Radiation - Cytotoxic therapies cause immunosuppression; Tα1 co-administration restores immune function, reduces infection risk, and may enhance anti-tumor immunity by promoting immunogenic cell death recognition. Research examines whether Tα1 reduces chemotherapy-induced lymphopenia or radiation-induced immune suppression. (3) Tα1 + Interferon-Alpha (IFN-α) - Synergistic antiviral effects in chronic hepatitis B/C research. Tα1 promotes DC activation and Th1 immunity while IFN-α provides direct antiviral effects; combination shows improved HBsAg seroconversion and sustained virological response rates vs monotherapy. (4) Tα1 + Cancer Vaccines - Tα1's DC-activating properties make it ideal vaccine adjuvant. Combining with tumor antigen vaccines (peptide vaccines, DC vaccines, whole tumor cell vaccines) enhances antigen presentation, T-cell priming, and memory formation. Research co-administers Tα1 with cancer vaccines measuring improved antigen-specific T-cell responses and tumor regression. (5) Tα1 + Interleukin-2 (IL-2) - IL-2 promotes T-cell expansion while Tα1 enhances T-cell activation and cytokine production; combination investigated in cancer immunotherapy and HIV research examining synergistic immune reconstitution. (6) Tα1 + Thymosin Beta-4 - Combining immune activation (Tα1) with tissue repair/anti-inflammatory effects (TB-500) in wound healing or post-surgical models where both infection resistance and tissue regeneration are desired. (7) Tα1 + Antibiotics/Antivirals - In sepsis or severe infection research, Tα1 prevents immunoparalysis maintaining immune cell function while antimicrobials control pathogen burden. (8) Tα1 + CAR-T therapy - Investigating whether Tα1 pre-conditioning or co-administration enhances CAR-T cell expansion, persistence, and cytotoxicity in solid tumor models.

How does Thymosin Alpha-1 modulate Th1/Th2 balance and what research benefits from this?

Thymosin Alpha-1 is a potent Th1-biasing immunomodulator with important research applications: (1) Mechanism of Th1 polarization - Tα1 activates dendritic cells via TLR2/TLR9 triggering MyD88-NF-κB-IRF signaling pathways that upregulate IL-12 production. IL-12 is the master Th1-polarizing cytokine; it activates STAT4 in naive CD4+ T-cells inducing T-bet transcription factor expression which commits cells to Th1 lineage characterized by IFN-γ, IL-2, TNF-α secretion. Simultaneously, Tα1 reduces IL-4 and IL-10 (Th2 cytokines) shifting the Th1/Th2 ratio toward cell-mediated immunity. (2) Flow cytometric validation - Researchers use intracellular cytokine staining after Tα1 treatment showing increased IFN-γ+ CD4+ T-cells (Th1) and decreased IL-4+ CD4+ T-cells (Th2) compared to untreated controls, quantifying the Th1/Th2 ratio shift. (3) Infectious disease research - Intracellular pathogens (mycobacteria, listeria, toxoplasma, viruses) require Th1 immunity for clearance (IFN-γ activates macrophages increasing microbicidal activity, CTLs kill infected cells). Tα1 treatment in these models enhances pathogen clearance, reduces bacterial/viral loads, and improves survival. Conversely, extracellular parasites (helminths) or allergens typically require Th2 responses (IL-4, IL-5, IgE, eosinophils); inappropriate Th1 bias from Tα1 could worsen these conditions - research must consider infection type. (4) Allergy and asthma research - Allergic diseases involve excessive Th2 responses (IL-4, IL-5, IL-13) causing IgE production, eosinophilia, airway hyperreactivity. Tα1's Th1-promoting effects can counterbalance Th2 skewing; studies in murine asthma models (ovalbumin sensitization) show Tα1 administration reduces airway inflammation, eosinophil infiltration, and IgE levels by restoring Th1/Th2 balance. (5) Autoimmune disease research - Different autoimmune diseases have distinct Th1/Th2 profiles. Th1-mediated autoimmunity (type 1 diabetes, rheumatoid arthritis, multiple sclerosis) involves IFN-γ-driven tissue damage; excessive Tα1 could worsen these. However, Tα1 also induces regulatory T-cells (Tregs, CD4+CD25+Foxp3+) which suppress both Th1 and Th2 responses preventing autoimmune pathology. Research examines this paradox: Tα1 promotes Th1 but also Tregs, and the net effect depends on dose, timing, and disease model. (6) Cancer immunotherapy - Anti-tumor immunity requires Th1 responses (IFN-γ, CTLs, NK cells); tumors often create immunosuppressive Th2-skewed environments. Tα1 reverses this by promoting Th1 cytokines, activating CTLs and NK cells, and reducing Th2/Treg-mediated suppression. (7) Experimental design - Researchers measure Th1/Th2 ratios using ELISA for IFN-γ/IL-4, flow cytometry for intracellular cytokines, or quantitative PCR for transcription factors (T-bet/GATA3 ratio). Tα1 dose-response studies identify optimal concentrations for Th1 polarization without excessive inflammation.

What documentation and international shipping support Thymosin Alpha-1 immune research?

We ship Thymosin Alpha-1 in lyophilized form with cold pack insulation in sealed packaging protecting the 28-amino-acid immunomodulatory peptide. Lyophilized Tα1 with N-terminal acetylation remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation. International delivery typically takes 10-14 days with tracking; immediately transfer to -20°C storage upon arrival. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the 28-AA sequence, mass spectrometry data confirming molecular weight (~3108 Da) validating the complete Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn sequence and critically confirming N-terminal acetylation (mass spectra shows +42 Da from acetyl group; non-acetylated forms show reduced bioactivity and faster degradation), peptide sequencing via MS/MS fragmentation or Edman degradation verifying each amino acid residue and confirming N-terminal blocking (acetylated serine shows no PTH-amino acid release in first Edman cycle), amino acid composition analysis quantifying each residue, functional bioassay data demonstrating immunological activity including dendritic cell maturation assays (CD80/CD86/MHC-II upregulation, IL-12 production with EC50 quantification), Th1 cytokine production assays (IFN-γ, IL-2 secretion from PBMCs/splenocytes validating Th1-polarizing activity), TLR reporter assays confirming TLR2/TLR9 agonist function via NF-κB-luciferase activation, NK cell cytotoxicity enhancement demonstrating increased tumor cell lysis, endotoxin testing (<0.1 EU/mg), batch number and manufacturing date. This documentation satisfies institutional requirements worldwide ensuring compliance for innate immunity research, TLR signaling studies, vaccine adjuvant development, infectious disease models, cancer immunotherapy investigations, and immunodeficiency research. For researchers requiring technical support on immunological assay development or Th1 polarization optimization, our team provides WhatsApp consultation on experimental design, optimal dosing for DC activation vs T-cell modulation, and cytokine analysis protocols.

What dosage specifications and bulk pricing are available for Thymosin Alpha-1 research?

We offer two Thymosin Alpha-1 specifications to accommodate diverse immunological research protocols: TA5 (5mg per 10-vial kit) and TA10 (10mg per 10-vial kit). Pricing with volume discounts: TA5: $160/kit (1 kit), $150/kit (20+ kits = 6.3% discount), $145/kit (50+ kits = 9.4% discount). TA10: $265/kit (1 kit), $255/kit (20+ kits = 3.8% discount), $250/kit (50+ kits = 5.7% discount). The dual concentration options support research from pilot TLR signaling assays and DC activation dose-response studies (lower concentrations for in vitro screening) to extensive immunological protocols investigating vaccine adjuvant effects, chronic viral infection models, cancer immunotherapy combinations, and large-scale animal sepsis or immunodeficiency research (higher concentrations). Pricing reflects synthesis complexity of the 28-amino-acid peptide requiring solid-phase peptide synthesis (SPPS) assembling 28 residues with specific sequence including charged residues (Asp, Glu, Lys) that can cause coupling difficulties, N-terminal acetylation (chemical or enzymatic modification essential for aminopeptidase resistance and TLR bioactivity - non-acetylated forms show 5-20 fold reduced potency), rigorous quality control (HPLC purity, mass spec confirming sequence and N-terminal acetyl group, peptide sequencing, amino acid analysis, comprehensive immunological bioassays including DC maturation measuring CD80/CD86/IL-12 with EC50 quantification, Th1 cytokine production quantifying IFN-γ/IL-2, TLR reporter assays confirming TLR2/TLR9 activation, NK cytotoxicity assays), and comprehensive CoA documentation while maintaining >98% purity. Bulk discounts support multi-year immunotherapy research programs, institutional vaccine development facilities, pharmaceutical companies developing Tα1 combinations with checkpoint inhibitors or DC vaccines, and international infectious disease research consortia. Contact via WhatsApp for custom quantities for large animal viral infection studies or clinical research requiring GMP-grade material for investigational new drug (IND) applications.

Home ProductsThymosin Alpha-1

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

TA15

Thymosin Alpha-1

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade Thymosin Alpha-1 for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $250/kit

+$190

extra savings

Total Price

$345

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.52% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

Thymosin Alpha-1: Key Facts

Thymosin Alpha-1 is a immune support research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 2 formats starting at $345 per kit. Each batch is independently HPLC-verified at 99.52% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	Thymosin Alpha-1
Research category	Immune Support
Available formats	5mg10vials, 10mg10vials
Starting price	From $345 USD per kit
Purity	99.52% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Vikram Patel

Canada

"Our infectious disease research lab at an institutional research lab in Berlin has been using LyzeLabs Thymosin Alpha-1 for immunomodulation studies for 10 months with exceptional pharmaceutical quality. We independently verified >98.6% purity via HPLC and mass spectrometry confirmed the 28-amino-acid structure with molecular weight 3108 Da demonstrating proper N-terminal acetylation (critical for aminopeptidase resistance - non-acetylated forms degrade 10-fold faster). Our research investigates Tα1 as adjuvant for tuberculosis vaccine development - dendritic cell maturation assays show Tα1 (1-10 μg/mL) dose-dependently upregulates CD80, CD86, and MHC-II expression (3.2-fold increase vs untreated, p<0.001 by flow cytometry) and increases IL-12 secretion (EC50 ~280 nM via ELISA). TLR reporter assays using HEK293-TLR2-NF-κB-luciferase cells confirm Tα1 activates TLR2 signaling with robust dose-dependent luciferase induction. Mouse immunization studies combining BCG vaccine + Tα1 adjuvant demonstrate enhanced Th1 responses (IFN-γ+ CD4+ T-cells increased 4.1-fold, p<0.001) and improved mycobacterial clearance vs BCG alone. Cytokine multiplex assays show Tα1 skews toward Th1 profile (elevated IFN-γ, IL-2, TNF-α) while reducing Th2 cytokines (IL-4, IL-10). We're also testing Tα1 in sepsis models - treatment prevents immunoparalysis maintaining monocyte HLA-DR expression and restoring cytokine production capacity. The TA10 specification supports our chronic dosing protocols. Delivery to Berlin takes 10-12 days with excellent cold-chain packaging. Premier immunomodulatory peptide for international vaccine and infection research."

2025-11-12

Jonas W.

United States

"Checked identity and purity ourselves. Both lined up with the COA."

2025-11-09

Felix R.

Sweden

"Third order now. Quality hasn't wandered, which is the only thing I care about."

2025-11-06

About This Product

Thymosin Alpha-1 Research Guide

The Immune Research Peptide From the Thymus

Thymosin Alpha-1 is a synthetic 28 amino acid peptide originally isolated from the thymus gland, where it plays a role in the maturation and function of T lymphocytes. Unlike Thymosin Beta-4 (which gives rise to the TB-500 research fragment and acts primarily through actin sequestration for tissue repair), Thymosin Alpha-1 acts on the immune system and is the research peptide of choice for protocols investigating T-cell function and immune modulation.

Mechanism

T-cell maturation: modulates the differentiation and maturation of T lymphocytes in research models, which is the central role of thymic peptides in the immune system
Toll-like receptor signaling: documented effects on TLR2 and TLR9 signaling in research models, connecting the compound to innate as well as adaptive immunity
Cytokine modulation: shifts cytokine profiles toward responses associated with effective antiviral and anticancer immune function
Dendritic cell activation: effects on antigen-presenting cell biology that bridge innate and adaptive immunity

Research Applications

T-cell biology and lymphocyte maturation research
Immune modulation protocols, particularly those focused on restoring immune function in compromised research models
Viral infection research where T-cell response is a key outcome measure
Comparative research against other thymic peptides like [Thymalin](/product/thymalin)
Anticancer immune research protocols
Combination research with other immunomodulatory compounds

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For research purposes only. Not for human consumption or therapeutic use.

Research Context for Thymosin Alpha-1

Immune Modulation Research Context

Immune research peptides are studied for effects on T-cell maturation, innate immune response, cytokine signaling, and the thymic-derived immune modulation pathway. Protocols in this category often involve longitudinal immune biomarker tracking and specific infection or inflammation models.

Thymosin Alpha-1 ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Immune Support category, with 2 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Immune Support Category

LL37

Thymalin

Research Tools for This Compound

Frequently Asked Questions

Thymosin Alpha-1

$345